Enveric Biosciences appoints Kevin Coveney as CFO effective March 13, 2023; interim CFO Robert Dickey IV resigns

Enveric Biosciences, Inc.

Kevin Coveney appointed CFO effective March 13, 2023, succeeding interim CFO Robert Dickey IV.
Coveney receives $385,000 base salary, bonus up to 40% of base, and 26,500 RSUs vesting over 4 years.
Coveney brings 30+ years biotech finance experience; previously CFO at Memgen and Q-State Biosciences.
Interim CFO Robert Dickey IV resigns; resignation not due to any disagreement with company.
Inducement RSU grant approved by board under NASDAQ Listing Rule 5635(c)(4).

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Kevin M. Coveney

chief financial officer

ENVB · Enveric Biosciences, Inc.

Effective: 2023-03-13
Filed: February 28, 2023, 6:59 PM ET

On February 22, 2023, Kevin M. Coveney, 59, was appointed as the chief financial officer of Enveric Biosciences, Inc. (the “Company”) effective March 13, 2023 (the “Effective Date”).

Departed (interim)

Robert Dickey IV

chief financial officer

ENVB · Enveric Biosciences, Inc.

Effective: 2023-03-13
Successor: Kevin M. Coveney
Filed: February 28, 2023, 6:59 PM ET

Effective as of the Effective Date, Robert Dickey IV will resign from his position as the Company’s chief financial officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Kevin M. Coveney was appointed as chief financial officer at Enveric Biosciences, Inc..

Action: appointed
Role: chief financial officer

Exact text from the filing

On February 22, 2023, Kevin M. Coveney, 59, was appointed as the chief financial officer of Enveric Biosciences, Inc. (the “Company”) effective March 13, 2023 (the “Effective Date”).

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Robert Dickey IV departed as chief financial officer at Enveric Biosciences, Inc..

Action: resign
Role: chief financial officer

Exact text from the filing

Effective as of the Effective Date, Robert Dickey IV will resign from his position as the Company’s chief financial officer.

View on SEC.gov

Enveric Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-006267

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.